Achieve Life Sciences (ACHV) is close to gaining FDA approval of cytisinicline as a safe, effective treatment for smoking addiction, Hunterbrook’s Nathaniel Horwitz, Laura Wadsten, and Michelle Cera report. The FDA has previously accepted the company’s anti-smoking application for review following two successful Phase 3 clinical trials as well as a successful longer-term safety study, the authors note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences initiated with an Outperform at Citizens JMP
- Promising Developments and Strategic Advancements Drive Positive Outlook for Achieve Life Sciences
- Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential
- Achieve Life Sciences Reports Q3 2025 Results
- Achieve Life Sciences: Key Insights from Earnings Call